on Novigenix AI
Novigenix AI Launches First AI-Powered Immune Intelligence Platform
Novigenix AI has been officially launched as a spin-out from Novigenix SA, aimed at revolutionizing precision medicine through AI-powered immune intelligence. The new company focuses on commercializing the LITOSeek® platform, an AI-enabled tool designed to understand systemic immune responses, offering insights for therapy development and patient care.
The separation allows Novigenix's colorectal cancer screening business to operate independently, while Novigenix AI targets the global biopharma and precision medicine markets. The LITOSeek® platform helps address therapy development challenges by providing actionable insights from blood samples.
With its ISO 13485 certification, LITOSeek® integrates advanced machine learning to offer real-time tracking of immune health and therapy responses, enhancing clinical trial operations. Novigenix AI's launch is bolstered by proven commercial success, with an eye on expanding to autoimmune and neurological diseases.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Novigenix AI news